Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors, page-43

Yep still cheap here less than $25M - pretty sure management will keep communication lines open but also still very pre-clinical like trial results wont see anything put humans for probably a year or two - further mouse models, toxicology, stability etc as stated by company - not sure when they move for cash but i'm sure they'll be smart having learnt from the last pineapple CR move they made a few years ago.

PRR as you mentioned it is a good topic too I expect that to go 5-10x in coming weeks, months stupidly undervalued and forgotten -as well. They have $12M cash 2 big pharma partners GSK / Novartis, 4 separate clinical trials underway in humans, LAG-3 founder, former Bank Of America / Meril Lynch head of M&A just appointed to board and multiple broker targets around the $0.10 mark - $50M @ $0.022.